---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-067130"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2025-07-24T23:59:59+00:00"
generated_at: "2026-05-18T02:27:43.974984+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aditxt CEO presents autoimmunity unit Adimune; stock at $5M market cap

## Summary
- CEO presented at Wall Street Reporter livestream on July 22, 2025, focusing on subsidiary Adimune.
- Adimune aims to reprogram immune system for autoimmune diseases; currently preclinical with human trials as key catalyst.
- Other catalysts: Pearsanta cancer detection spin-off IPO and Adifem (Evofem) acquisition close expected Sept 2025.
- CEO believes stock's ~$5M market cap is disconnected from value proposition; multiple shots on goal.
- Adimune approach contrasts with traditional immunosuppressants; results from human trials awaited.

## SEC filing metadata
- accession: 0001213900-25-067130
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2025-07-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390025067130/0001213900-25-067130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390025067130/ea0250052-8k_aditxt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-067130
- JSON: https://secwatch.observer/filing/0001213900-25-067130.json
- Plain text: https://secwatch.observer/filing/0001213900-25-067130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.